Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent

Chemistry and Biology

Volumn 7, Issue 1, 2000, Pages 51-63

  Meijer, L ^a   Thunnissen, A M W H ^b   White, A W ^c   Garnier, M ^a   Nikolic, M ^d   Tsai, L H ^d   Walter, J ^e   Cleverley, K E ^f   Salinas, P C ^f   Wu, Y Z ^g   Biernat, J ^g   Mandelkow, E M ^g   Kim, S H ^b   Pettit, G R ^c  

^a CNRS   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e Ctrl Institute of Mental Health J5   (Germany)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g MAX PLANCK UNIT FOR STRUCTURAL MOLECULAR BIOLOGY   (Germany)

Author keywords

Alzheimer's disease; Cyclin dependent kinases; Glycogen synthase kinase; Hymenialdisine; Tau

Indexed keywords

ANIMALIA; PORIFERA;

EID: 0034010742     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(00)00063-6     Document Type: Article

References (75)

1. Selkoe D.J. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8:1998;447-453.
2. Imahori K., Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. 121:1997;179-188.
3. Mandelkow E.-M., Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol. 8:1998;425-427.
4. Singh T.J., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau protein by casein kinase 1 converts it to an abnormal Alzheimer-like state. J. Neurochem. 64:1995;1420-1423.
5. Haas C., Mandelkow E. Proteolysis by presenilins and the renaissance of tau. Trends Cell Biol. 9:1999;241-244.
6. Anderton B.H. Alzheimer's disease: clues from flies and worms. Curr. Biol. 9:1999;R106-R109.
7. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., Selkoe D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature. 398:1999;513-517.
8. Yu G., Fraser P.E.et al. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains β-catenin. J. Biol. Chem. 273:1998;16470-16475.
9. Zhang Z.H., Yankner B.A.et al. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature. 395:1998;698-702.
10. Takashima A., Wolzonin B.et al. Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau. Proc. Natl Acad. Sci. USA. 95:1998;9637-9641.
11. Takashima A., Yamaguchi H.et al. Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res. 31:1998;317-323.
12. Ebneth A., Mandelkow E.et al. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol. 143:1998;777-794.
13. Hudkins R.L. ATP-site directed kinase inhibitors for therapeutic intervention. Curr. Med. Chem. 6:1999;773-903.
14. Dunphy W.G. Methods in Enzymology: Cell-Cycle Control. 1997;Academic Press, New York.
15. Morgan D. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13:1997;261-291.
16. Vogt P.K., Reed S.I. Current Topics in Microbiology and Immunology: Cyclin-Dependent Kinase (CDK) Inhibitors. 1998;Springer Verlag, Berlin.
17. Garcia-Perez J., Avila J., Diaz-Nido J. Implications of cyclin-dependent kinases and glycogen synthase kinase 3 in the phosphorylation of microtubule-associated protein 1B in developing neuronal cells. J. Neurosci. Res. 52:1998;445-452.
18. Nikolic M., Chou M.M., Lu W., Mayer B.J., Tsai L.-H. The p35/cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature. 395:1998;194-198.
19. Qi Z., Tang D.M., Zhu X.D., Fujita D.J., Wang J.H. Association of neurofilament proteins with neuronal Cdk5 activator. J. Biol. Chem. 273:1998;2329-2335.
20. Meijer L., Kim S.H. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol. 283:1997;113-128.
21. Garrett M.D., Fattaey A. CDK inhibition and cancer therapy. Curr. Opin. Gene. Dev. 9:1999;104-111.
22. Gray N.S., Détivaud L., Doerig C., Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6:1999;859-875.
23. Vesely J., Meijer L.et al. Inhibition of cyclin-dependent kinases by purine derivatives. Eur. J. Biochem. 224:1994;771-786.
24. Meijer L., Moulinoux J.P.et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:1997;527-536.
25. De Azevedo W.F., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S.-H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243:1997;518-526.
26. Gray N.S., Schultz P.G.et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538.
27. Losiewiecz M.D., Carlson B.A., Kaur G., Sausville E.A., Worland P.J. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201:1994;589-595.
28. Hoessel R., Meijer L.et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1:1999;60-67.
29. Zaharevitz D., Sausville E.A.et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59:1999;2566-2569.
30. Schultz C., Kunick C.et al. The Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 42:1999;2909-2919.
31. Pettit G.R., Boyd M.R.et al. Antineoplastic agents. 362. Isolation and X-ray crystal structure of dibromophakellstatin from the Indian Ocean sponge Phakellia mauritiana. J. Nat. Prod. 60:1997;180-183.
32. Pettit G.R. Progress in the discovery of biosynthetic anticancer drugs. J. Nat. Prod. 59:1996;812-821.
33. Sharma G.M., Buyer J., Pomerantz M.W. Characterization of a yellow compound isolated from the marine sponge Phakellia flabellata. J. Chem. Soc. Chem. Commun. 1980;435-436.
34. Cimino G., de Rosa S., de Stefano S., Mazzarella L., Puliti R., Sodano G. Isolation and X-ray crystal structure of a novel bromo-compound from two marine sponges. Tetrahedron Lett. 23:1982;767-768.
35. Kitagawa I., Kobayashi M., Kitanaka K., Kido M., Kyogoku Y. Marine natural products. XII. On the chemical constituents of the Okinawan marine sponge Hymeniacidon aldis. Chem. Pharm. Bull. 31:1983;2321-2328.
36. Pettit G.R., Camou F.et al. Antineoplastic agents. 168. Isolation and structure of axinohydantoin. Can. J. Chem. 68:1990;1621-1624.
37. Williams D.H., Faulkner J. Isomers and tautomers of hymenialdisine and debromohymenialdisine. Nat. Prod. Lett. 9:1996;57-64.
38. Carlson B.A., Dubay M.M., Sausville E.A., Brizuela L., Worland P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56:1996;2973-2978.
39. Walter J., Grünberg J., Schindzielorz A., Haass C. Proteolytic fragments of the Alzheimer's disease associated presenilins-1 and-2 are phosphorylated in vivo by distinct cellular mechanisms. Biochemistry. 37:1998;5961-5967.
40. Eldar-Finkelman H., Krebs E.G. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc. Natl Acad. Sci. USA. 94:1997;9660-9664.
41. Schulze-Gahmen U., Kim S-H.et al. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins. 22:1995;378-391.
42. De Azevedo W.F., Mueller-Dieckmann H.J., Schulze-Gahmen U., Worland P.J., Sausville E., Kim S.-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl Acad. Sci. USA. 93:1996;2735-2740.
43. Lawrie A.M., Noble M.E., Tunnah P., Brown N.R., Johnson L.N., Endicott J.A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 4:1997;796-801.
44. Ramachandran G.N., Ramakrishnan C., Sasisekharan V. Stereochemistry of polypeptide chain configurations. J. Mol. Biol. 7:1963;95-99.
45. Schulze-Gahmen U., De Bondt H.L., Kim S.-H. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J. Med. Chem. 39:1996;4540-4546.
46. Russo A.A., Jeffrey P.D., Pavletich N.P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 3:1996;696-700.
47. Hanks S.K., Hunter T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9:1995;576-596.
48. Patrick G.N., Zhou P., Kwon Y.T., Howley P.M., Tsai L.-H. p35, the neuronal activator of CDK5, is degraded by the ubiquitin-proteasome pathway. J. Biol. Chem. 273:1998;24057-24064.
49. Lucas F.R., Salinas P.C. WNT-7a induces axonal remodelling and increases synapsin I levels in cerebellar neurons. Dev. Biol. 193:1997;31-44.
50. Lucas F.R., Goold R.G., Gordon-Weeks P.R., Salinas P.C. inhibition of GSK-3β leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J. Cell Sci. 111:1998;1351-1361.
51. Zheng-Fischhöfer Q., Biernat J., Mandelkow E.-M., Illenberger S., Godemann R., Mandelkow E. Sequential phosphorylation of tau-protein by GSK-3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT-100 and requires a paired helical filament-like conformation. Eur. J. Biochem. 252:1998;542-552.
52. Braekman J.C., Daloze D., Stoller C., Van Soest R.W.M. Chemotaxonomy of Agelas (Porifera: Demospongiae). Biochem. Syst. Ecol. 20:1992;417-431.
53. Chanas B., Pawlik J.R., Lindel T., Fenical W. Chemical defense of the carribean sponge Agelas clathrodes (Schmidt). J. Exp. Mar. Biol. Ecol. 208:1996;185-196.
54. Annoura H., Tatsuoka T. Total syntheses of hymenialdisine and debromohymenialdisine: stereospecific construction of the 2-amino-4-oxo-2-imidazolin-5(Z)-disubstituted ylidene ring system. Tetrahedron Lett. 36:1995;413-416.
55. Matsuki S., Mizuno A., Annoura H., Tatsuoka T. Synthesis of pyrroloazepines. Facile synthesis of 2-substituted pyrrole derivatives by the phosgene method. J. Heterocyclic Chem. 34:1997;87-91.
56. 5 marine sponge alkaloids: (±)-hymenin, stevensine, hymenialdisine, and debromohymenialdisine. J. Org. Chem. 62:1997;456-464.
57. Brion J.P., Couk A.M. Cortical & brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am. J. Pathol. 147:1995;1465-1476.
58. Nakamura S., Kawamoto Y., Nakano S., Akiguchi I., Kimura J. Cyclin-dependent kinase 5 and mitogen-activated protein kinase in glial cytoplasmic inclusions in multiple system atrophy. J. Neuropathol. Exp. Neurol. 57:1998;690-698.
59. Green S.L., Vulliet P.R., Pinter M.J., Cork L.C. Alterations in cyclin-dependent protein kinase 5 (CDK5) protein levels, activity and immunocytochemistry in canine motor neurone disease. J. Neuropathol. Exp. Neurol. 57:1998;1070-1077.
60. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl Acad. Sci. USA. 93:1996;8455-8459.
61. Hong M., Chen D.C., Klein P.S., Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272:1997;25326-25332.
62. Munoz-Montano J.R., Moreno F.J., Avila J., Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411:1997;183-188.
63. Lovestone S., Anderton B.H.et al. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol. Psychiatry. 45:1999;995-1003.
64. Cohen P. The Croonian lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. Phil. Trans. R. Soc. Lond. B. 354:1999;485-495.
65. Breton J.J., Chabot-Fletcher M.C. The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-B. J. Pharmacol. Exp. Therap. 282:1997;459-466.
66. Roshak A., Jackson J.R., Chabot-Fletcher M., Marshall L.A. Inhibition of NFκB-mediated interleukin-1b-stimulated prostaglandin E2 formation by the marine natural product hymenialdisine. J. Pharmacol. Exp. Therap. 283:1997;955-960.
67. Di Martino M., Wolff C., Patil A., Nambi P. Effects of a protein kinase C inhibitor (PKCI) on the development of adjuvant-induced arthritis (AA) in rats. Inflamm. Res. 2:1995;S123-S124.
68. Rosenblatt J., De Bondt H.L., Jancarik J., Morgan D.O., Kim S.-H. Crystal structure of cyclin-dependent kinase 2. Purification and crystallization of human cyclin-dependent kinase 2. J. Mol. Biol. 230:1993;1317-1319.
69. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
70. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760-763.
71. Brünger A.T. X-PLOR, Version 3.1. A System for Protein Crystallography and NMR. 1993;Yale University Press, New Haven, CT.
72. Mattia C.A., Mazzarella L., Puliti R. 4-(2-amino-4-oxo-2-imidazolin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo-[2,3- c]azepin-8-one methanol solvate: a new bromo compound from the sponge Acanthella aurantiaca. Acta Crystallogr. B. 38:1982;2513-2515.
73. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:1993;283-291.
74. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., Kim S.H. Crystal structure of cyclin-dependent kinase 2. Nature. 363:1993;595-602.
75. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:1991;946-950.